Viread at Biology Products
Viread at Biology Technology
Viread at Medicine News
FDA Approves New HIV Drug, Viread
Biopharmaceutical firm Gilead Sciences Inc. said it has received approval from the US Food and Drug Administration (FDA) to market its antiretroviral agent
Viread (tenofovir disoproxil fumarate) for the treatment of HIV in combination with other antiretroviral agents. Like
Viread, such drugs work by blocking the process needed for HIV replication in the body. But
Viread is the first nu...
Use Of Viread Spreads As New Anti-AIDS Site Is Launched
A website has been unveiled by the Los Angeles County health officials which will facilitate the sending of e-mails to keep people informed of HIV and other related diseases. The site called, inSPOTLA.org is meant // to check the spread of the diseases, and encourage safe sex. The site is targeted at people seeking casual sex on line. A similar site launched in San Francisco in 2004...
Viread To Retail In India For $1
The largest-selling HIV/AIDS drug,
Viread is to be made available in India at the special price of $1 (Rs 45) per tablet, according to the manufacturer Gilead.// This announcement was made on Sunday. Gilead has already entered into generic licensing deals with three Indian pharma majors - Emcure Pharmaceuticals, Hetero Drugs and Strides Arcolab - for the drug. The Indian firms will ma...
Viread at Medicine Products
Viread at Medicine Technology
Second Phase III Study Evaluating Gilead's Viread for the Treatment
of Chronic Hepatitis B Virus Meets Primary Endpoint
FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug
Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat
Viread...
Second Phase III Study Evaluating Gilead's Viread for the Treatment
of Chronic Hepatitis B Virus Meets Primary Endpoint
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug
Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat
Viread is...
Phase III Study Evaluating Gilead's Viread for the Treatment of
Chronic Hepatitis B Virus Meets Primary Endpoint
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 102, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug
Viread (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The study showsthat
Viread is no...